

CONTRIBUTORS

- N. R. Di Luzio, Ph.D.,
Department of Physiology,
Tulane University School of Medicine,
New Orleans, Louisiana.
- W. L. Dunn, M.D.,
Department of Pathology,
University of British Columbia,
Vancouver, British Columbia.
- Murray M. Fisher, M.D.,
Departments of Medicine and Pathology,
University of Toronto,
Toronto, Ontario.
- Roy A. Fox, M.D.,
Department of Medicine,
Dalhousie University,
Halifax, Nova Scotia.
- S. W. French, M.D.,
Department of Pathology,
Veterans Administration Hospital,
Martinez, California.
- Ellen R. Gordon, Ph.D.,
McGill University Medical Clinic
Montreal General Hospital,
Montreal, Quebec.
- Y. Israel, Ph.D.,
Department of Pharmacology,
University of Toronto,
Toronto, Ontario.

- Kurt J. Isselbacher, M.D.,
Department of Medicine,
Massachusetts General Hospital,
Boston, Massachusetts.
- Jean-Gil Joly, M.D.,
Clinical Research Center,
Hôpital Saint-Luc,
Montreal, Quebec.
- Harold Kalant, M.D.,
Department of Pharmacology,
University of Toronto,
Toronto, Ontario.
- J.M. Khanna, Ph.D.,
Department of Pharmacology,
University of Toronto,
Toronto, Ontario.
- Charles S. Lieber, M.D.,
Section of Liver Disease & Nutrition,
Veterans Administration Hospital,
Bronx, New York.
- K. Lindros, Ph.D.,
Research Laboratories of the
State Alcohol Monopoly,
Helsinki, Finland.
- Frank Lundquist, M.D.,
Department of Biochemistry A,
University of Copenhagen,
Copenhagen, Denmark.
- Shohei Matsuzaki, M.D.,
Section of Liver Disease & Nutrition,
Veterans Administration Hospital,
Bronx, New York.
- M. James Phillips, M.D.,
Department of Pathology,
University of Toronto,
Toronto, Ontario.
- Hans Popper, M.D.,
Mount Sinai School of Medicine of the
City University of New York,
New York, New York.

James G. Rankin, M.B.,
Addiction Research Foundation,
Toronto, Ontario.

Marcus A. Rothschild, M.D.,
Radioisotope Service,
New York Veterans Administration Hospital,
New York, New York.

Emanuel Rubin, M.D.,
Department of Pathology,
Mount Sinai School of Medicine of the
City University of New York,
New York, New York.

W. Schmidt, Dr. Jur., M.S.W.,
Addiction Research Foundation,
Toronto, Ontario.

INDEX

- Abstinence, 377
- Acetaldehyde, 32, 45, 58, 119,
149, 170, 195, 202, 225
- Acetaldehyde dehydrogenase, 160
- Acetate, 31, 45, 59, 145
- Adenine translocase, 146
- Albumin, serum, synthesis, 79, 84
- Alcohol,
 - consumption, 10, 366, 367,
372, 374
 - types of beverage, 27
- Alcohol dehydrogenase, 31, 64, 119
- Alcoholic hepatitis, 220, 261,
293, 299, 305, 325, 347,
349, 354
- Alcoholic liver disease,
 - management, 373, 388, 393
 - mortality, 367
 - natural history, 349
 - pathogenesis, 197, 258
 - prevention, 377, 388
 - prognosis, 373
 - recognition, 378
- Alcoholism, 389
 - prognosis, 376
- Aldehyde dehydrogenase, 64
- AMP, 41
- Anemia, 337
- Aniline, 109
- Antabuse, 47, 59, 147, 384
- Antibody, smooth muscle, 263
- Antigens, 263
- Antioxidant, 58, 164
- Arginine, 79, 81
- ATP Synthesis, 34, 68, 91, 155
- Auto antibodies, 310
- Azide, 124
- Baboons, 230
- Benzphetamine, 104
- Benzpyrene, 109
- Bilirubin, 212
- Biopsy, liver, 264, 374
- Biotransformation, 101
- Bleeding varices, 349
- Blood flow,
 - hepatic, 162
 - portal, 363
- BSP, plasma, 47
- Carbohydrate metabolism, 39
- Carbon tetrachloride, 207, 291
- Carcinogenesis, 390
- Carcinoma,
 - hepatocellular, 301, 392
- Catalase, 32, 33, 119, 157
- Central hyaline sclerosis, 229, 295
- Chemiluminescence, 47, 53
- Cholesterol metabolism, 209
- Cirrhosis, 92, 227, 349
 - epidemiology, 1, 388
 - mortality, 1, 368
 - sex difference, 15, 28, 367
 - definition, 289
- Colchicine, 261
- Collagen, 199, 290
- Congener, 29, 390
- Contractile protein, 196
- Corticosteroid treatment, 354
- Cytochrome P-450, 101, 147
- Diet,
 - experimental, 153, 156, 159, 216
- Disulfiram, 47, 59, 147, 384
- Drugs, 20, 101, 391

- Education, medical, 378
 Electron microscopy, 262
 Empty calorie, 154
 Endoplasmic reticulum, 79, 81,
 101, 167, 169, 206
 Endotoxemia, 391
 Enzymes, microsomal drug
 metabolising, 207
 Ethanol,
 blood disappearance, 134, 164
 consumption, chronic, 71, 101,
 119
 diet, 47, 59
 effect on albumin synthesis, 80
 Ethanol metabolism, 31
 rate, 206
 rate-limiting step, 63, 154, 323
 redox state, 63
 species differences, 153
 specific dynamic action, 145

 Fatty acids, 35, 39, 104, 174, 185
 Fatty liver, 45, 47, 59, 163, 169,
 199, 213, 292, 294, 364,
 390
 Fibrinogen, 92
 Fibrosis, 290, 388, 391
 Filament, 262
 Formazan, 176
 Free radicals, 390
 Fructose, 37

 Galactose uptake, 41
 Genetic protection, 389
 Gluconeogenesis, 39
 Glucose metabolism 212
 Glucose-6-phosphatase, 213
 Glycerol phosphate cycle, 35
 Golgi complex, 167
 Griseofulvin, 262

 Hepatic circulation, 294
 Hepatitis B Surface Antigenemia, 27
 Hepatitis, chronic active, 226
 Hepatocellular carcinoma, 301
 Hepatocytes, isolated, 37, 123, 148
 Hepatology, 387
 Hexobarbital, 109
 Hyaline, alcoholic, 229, 261, 297,
 313, 321, 330, 393

 Hyperlactacidemia, 198
 Hyperlipemia, 209
 Hyperlipidemia, 391
 Hypermetabolic state, 68, 151, 333,
 335, 390
 Hyperuricemia, 198
 Hypoglycemia, alcoholic, 39
 Hypoxia, 147, 327, 347

 Immunity, 226, 297, 309, 310, 388, 391
 Immunodiffusion, 263
 Immunofluorescent, 262
 Induction, 104
 Iron overload, 299
 Ischemia, 335
 Isoenzymes, 32
 Isotope effect, 32

 Ketoacidosis, 221, 357, 363
 Ketogenesis, 174, 183
 Kwashiorkor, 228

 Lipid peroxidation, 45, 58, 59, 146, 208
 Lipids, dietary, 104
 Lipocytes, 291
 Lipotropic factors, 217
 Liver,
 antioxidant levels, 58
 biopsy, 264, 374
 isolated perfused, 81, 325
 regeneration, 390
 slices, 127, 325
 Lymphocytes, 226, 261, 264, 287

 Malabsorption, 257
 Malate shuttle, 35
 Malnutrition, 156, 197, 228, 391
 Membranes, 187, 321, 390
 MEOS, 32, 33, 109, 119, 199
 Methylcholanthrene, 101
 Methylpyrazole, 159
 Microfilament, 262, 390
 Microsomal drug metabolising
 enzymes, 207
 Microsomes, 107
 Microtubules, 219, 261
 Mitochondria, 161, 169, 171, 195, 221

 Necrosis, 348, 388
 Nucleus, 79

- Ornithine, 81
- Oxidative phosphorylation, 222
- Oxygen,
 - consumption, 323, 336
 - gradient, 348
 - uptake, 171
- Perfused liver, isolated, 81, 325
- Phalloidin, 262
- Phenobarbital, 101
- Phosphatidyl choline, 104
- Phospholipid, 101
- Propylthiouracil, 330
- Protein,
 - accumulation, 219
 - synthesis, 90, 220, 258
- Pyrazole, 45, 47, 59, 124, 148, 157
- Redox state, 195, 198, 223
- Reducing equivalents, 63
- Respiratory depression, 338
- Shunts, portasystemic venous, 351
- Shuttle systems, 35, 67
- Spermine, 86
- Terminology, 151
- Thermic effect, 34
- Thyroid hormones, 67, 347
- Transferrin, 92
- Transhydrogenation, 37
- Vinyl chloride, 393